Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 485 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Lupus Erythematosus (Sle) Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus

NCT00723671
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Fibromyalgia, Acute Neuropsychiatric Lupus
Interventions
MRI
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 10, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Belimumab Assessment of Safety in SLE

NCT01705977
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
4,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
49
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 10, 2026, 2:08 PM EDT
Withdrawn Phase 3 Interventional

Study of Epratuzumab in Systemic Lupus Erythematosus

NCT00382837
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 10, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lupus Genetics Studies

NCT00071175
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
Not listed
Enrollment
3,460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 10, 2026, 2:08 PM EDT
Enrolling by invitation Phase 1 Interventional

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

NCT06518668
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
NKX019, Cyclophosphamide LD
Biological · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 10, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

NCT06544330
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
Interventions
SYNCAR-001, STK-009
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
6
States / cities
Scottsdale, Arizona • Hackensack, New Jersey • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 10, 2026, 2:08 PM EDT
Recruiting Not applicable Interventional

Intervention to Improve Communication and Medication Adherence in Lupus

NCT06458075
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
CO-LEAD
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 10, 2026, 2:08 PM EDT
Completed No phase listed Observational

Belimumab (BENLYSTA®) Pregnancy Registry

NCT01532310
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
2
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 10, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

NCT02070978
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 mg, Atacicept 150 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Anniston, Alabama • Birmingham, Alabama • Beverly Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 10, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

NCT02953821
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Acthar Gel, Placebo Gel
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Hemet, California • Upland, California • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 10, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

NCT06064929
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Felzartamab
Drug
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 10, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of ITGAM in Systemic Lupus Erythematosus

NCT01230112
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 10, 2026, 2:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
39
States / cities
La Jolla, California • La Mesa, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 10, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus

NCT00007358
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Atrioventricular Nodal Dysfunction, Myocardial Injury
Interventions
Dexamethasone or other corticosteroid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
4
States / cities
New Haven, Connecticut • Livingston, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 10, 2026, 2:08 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Obexelimab, Placebo
Drug
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
32
States / cities
Peoria, Arizona • Fresno, California • Huntington Park, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 10, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 10, 2026, 2:08 PM EDT
Terminated Phase 3 Interventional

Study of Epratuzumab in Systemic Lupus Erythematosus

NCT00111306
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
epratuzumab
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 10, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Results available

Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients

NCT01741012
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Gardasil
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 10, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01484496
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Belimumab 200 mg SC, Standard therapy
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
82
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 10, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

NCT02633163
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 10, 2026, 2:08 PM EDT
Completed No phase listed Observational

Health-related Quality of Life Measure in Pediatric Lupus

NCT00280137
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Quality of Life
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
2 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 10, 2026, 2:08 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Peer Approaches to Lupus Self-management

NCT03734055
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Quality of Life, Behavior, Health
Interventions
Peer Mentoring, Social Support Group
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 10, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

NCT00519363
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
atorvastatin
Drug
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 10, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of M2951 in SLE

NCT02975336
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
42
States / cities
Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 10, 2026, 2:08 PM EDT